A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
Status:
Completed
Trial end date:
2019-02-20
Target enrollment:
Participant gender:
Summary
A study of PF-05082566, a 4-1BB agonist monoclonal antibody (mAb), in patients with solid
tumors or b-cell lymphomas, and in combination with rituximab in patients with CD20 positive
Non-Hodgkin's Lymphoma (NHL).